| Session | Session Number | Number | Titel | Name |
| Session 1: Educational Session Feb., 26th, 09:00-12:00 | ||||
| 1 | INV1 | Converting an infectious retrovirus into a vehicle for modern therapeutics | Schambach, Axel | |
| 1 | INV2 | Adenovirus vectors | Kreppel, Florian | |
| 1 | INV3 | The AAV vector system | Büning, Hildegard | |
| INV4 | Oncolytic Viruses: Tailored for Targeted and Personalized Cancer Therapy | Nettelbeck, Dirk | ||
| 1 | INV5 | TCR gene therapy of cancer | Uckert, Wolfgang | |
| Session 2: Gene vector development and targeting Feb., 26th, 13:30-15:15 and 15:45-16:30 | ||||
| 2 | INV6 | Minimal position-specific adenovirus vector shielding -- how to limit systemic vector clearance and preserve vector infectivity | Kreppel, Florian | |
| 2 | INV7 | Receptor-targeted viral vectors for in vivo gene delivery | Buchholz, Christian | |
| 2 | OR1 | Exclusive transduction of human CD4+ T cells upon systemic delivery of CD4-targeted lentiviral vectors | Zhou, Qi | |
| 2 | OR2 | Targeted in vivo gene transfer into murine T cell subsets | Edes, Inan | |
| 2 | OR3 | Receptor-targeted lentiviral vectors based on engineered Nipah virus glycoproteins | Bender, Ruben | |
| 2 | OR4 | Oligo(alkyl amine) structures for mRNA-based therapeutics | Jarzebinska, Anita | |
| 2 | OR5 | The pCON-CENP-A vector system: long-term autonomous stability by active plasmid segregation | Hermann, Stefanie | |
| 2 | OR6 | Lentiviral vectors for platelet-directed expression by transcriptional targeting | Latorre Rey, Lisette Johana | |
| Session 3: Molecular imaging Feb., 26th, 16:30-17:15 | ||||
| 3 | INV8 | Optoacoustic Tomography: Light and sound for cancer imaging. | Bézière , Nicolas | |
| 3 | OR7 | A novel reporter system for monitoring of skeletal muscle differentiation | Öztürk-Kaloglu, Deniz | |
| Session 4: Plenary Lecture Feb., 26th, 17:30-18:15 | ||||
| 4 | INV9 | Development and optimization of oncolytic virus therapeutics | Bell, John | |
| Session 5: Oncolytic viruses Feb., 27th, 09:00-10:15 | ||||
| 5 | INV10 | Immunology restrictions of oncolytic virus therapy | von Laer, Dorothee | |
| 5 | OR8 | Immune checkpoint modulation enhances oncolytic Measles virus therapy | Engeland, Christine E. | |
| 5 | OR9 | Dual-Targeting of oncolytic Measles Viruses to EGFR-positive tumors using DARPins and MMP-activation | Muehlebach, Michael | |
| 5 | OR10 | Enhanced Vector Control Using MicroRNA Target Sites | Leber, Mathias | |
Session 6: Cancer immune(gene) therapy and cancer vaccines | ||||
| 6 | INV11 | T cell receptor gene therapy | Blankenstein, Thomas | |
| 6 | INV12 | Minimalistic vectors for nonviral cancer gene therapy: Phase I gene therapy trial for jet-injection gene transfer of the TNF-alpha expressing small-sized MIDGE vector in patients with in-transit metastases from melanoma | Walther, Wolfgang | |
| 6 | OR11 | The Viral Vector Vaccine VSV-GP Boosts the Immune Response upon Repeated Applications | Tober, Reinhard | |
| 6 | OR12 | Modifying TCR Specificity by TALEN and CRISPR | Knipping, Friederike | |
| 6 | OR13 | Targeted genome modifications for improved Adoptive Immunotherapy | Duchateau, Philippe | |
| Session 7: On the road towards clinical application Feb., 27th, 15:00-16:30 | ||||
| 7 | INV13 | Talimogene Laherparepvec - Intralesional Oncolytic Immunotherapy for the treatment of local and distantly metastatic melanoma | Putz, Thomas | |
| 7 | OR14 | Measuring viral titers by single particle analysis of virions | Heider, Susanne | |
| 7 | OR15 | Biodistribution of Advanced Therapy Medicinal Products (ATMPs): Workflow of a typical study at a professional pre-clinical service provider | Schreieck, Amelie | |
| 7 | OR16 | Relationship of rescue area size and visual information gain in gene therapy | Seeliger, Mathias | |
| 7 | OR17 | Development of a Gene Therapy Approach for Mucolipidosis Type II | Cornils, Kerstin | |
| Session 8: Update on clinical trials Feb., 27th, 17:00-18:15 | ||||
| 8 | INV14 | Use of oncolytic parvoviruses in the treatment of malignant gliomas | Rommelaere, J. | |
| 8 | INV15 | Gene Therapy of Cystic Fibrosis | Alton, Eric | |
| 8 | OR18 | Clinical Trial TREAT-ME 1: Treatment of Advanced Gastrointestinal Cancer in a Phase I/II trial with modified autologous MSC_apceth_101 | Franck, Thomas | |
| Session 9: Gene Therapy for chronic diseases Feb., 28th, 09:00-11:00 | ||||
| 9 | INV16 | Gene Therapy Approaches for the Treatment of Diabetes | Bosch, Fatima | |
| 9 | INV17 | Ischemic cardiomyopathy: gene-therapeutic options | Kupatt, Christian | |
| 9 | OR19 | Functional correction of X-SCID by targeted gene editing in pluripotent stem cells | Alzubi, Jamal | |
| 9 | OR20 | A 3'UTR mutation in factor IX elicits U1snRNP-mediated poly(A) site suppression leading to hemophilia B | Krooss, Simon | |
| 9 | OR21 | A novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5 in primary T cells after mRNA transfection | Fehse, Boris | |
| 9 | OR22 | AAV9-mediated gene transfer of wild type desmin ameliorates development of cardiomyopathy in desmin-deficient mice | Müller, Oliver | |
| Session 10: Latest developments in cell- and gene therapy Feb., 28th, 11:30-13:00 | ||||
| 10 | INV18 | Alpharetroviral vectors: A perspective for clinical application | Schambach, Axel | |
| 10 | INV19 | Safety of gene therapy with integrating vectors and preclinical models | Modlich, Ute | |
| 10 | OR23 | Culture-derived platelets differentiated from embryonic stem cells serve as potential tool for patient-specific cell therapy | Cullmann, Katharina | |
| 10 | OR24 | GENISP: Fully automated and efficient genome insertion site analysis tool | Afzal, Saira | |
Annual Meeting of the German Society of Gene Therapy | Universitätsring 1
| 1010 Wien